Seqera Labs, a Spanish provider of data orchestration and workflow software for life sciences, has landed €22 million in Series A funding. The financing round was led by Addition, with follow-on funding from Talis Capital, Speedinvest (which backed YardLink and cylib), BoxOne Ventures and Amino Collective.
Growth plans ahead
With this investment, Seqera Labs aims to move beyond scientific workflows to encompass tool development, data management, reporting, infrastructure deployment, and interactive computing.
The additional funding will help Seqera Labs bolster its team, as well as to expand its product portfolio to be able to cover the entire data analysis lifecycle. The raise builds on the €4.4 million raised in seed financing last year, and several grants from the Chan Zuckerberg Initiative, founded by Mark Zuckerberg and Dr. Priscilla Chan.
Evan Floden, Co-Founder and CEO at Seqera Labs, commented, “Partnering with Addition, alongside our existing investors, Speedinvest and Talis Capital, as well as Boxone and Amino, demonstrates their belief in our direction and our ability to execute. Our ambition is to develop a portfolio of innovative products that positively impact millions of patients worldwide by optimising drug research and discovery costs. We are delighted to be able to count on their support in achieving this goal.”
Jason Schneider, of Addition, added, “The biotechnology industry is undergoing a transformational shift and organisations must rapidly expand their capacity to process complex data at scale. Seqera Labs’ products make this easier than ever before and allow research teams to remain focused on their critical work. We’re proud to support Evan and his talented team as they continue on their impressive growth trajectory and lead breakthrough innovations in healthcare and life sciences.”
Kirill Tasilov, General Partner at Talis Capital, commented, “Seqera is rapidly becoming a de facto standard for complex data processing in life sciences and biology. We are beyond excited to continue supporting them on their journey of bringing the entire industry into the modern age.”
Deploys scalable data analysis pipelines
Founded in 2018 as a spin-off from the Centre for Genomic Regulation (CRG) by Evan Floden and Paolo Di Tommaso and is based in Barcelona and Toronto, after the success of Nextflow. Seqera Labs aims to accelerate discovery and therapeutic breakthroughs through foundational open science software. It is dedicated to empowering scientists to assemble and deploy massively scalable data analysis pipelines in multi-cloud environments with minimal friction.
Seqera Labs was pivotal to the Covid-19 variant detection with its technology used to discover and track Alpha, Delta and Omicron variants of the virus. Tower, the company’s flagship data analysis platform, has also managed to expand its footprint and achieve rapid adoption, being used by over 150 leading pharmaceutical and biotechnology companies, including AstraZeneca, Janssen Pharmaceuticals, and Oxford Nanopore.